Award Data

Individuals with cystic fibrosis (CF) and pancreatic insufficiency (PI) are prone to fat malabsorption, putting them at risk for caloric, essential fatty acid, and choline deficiency, which, in turn, may lead to growth failure and a poorer clinical course. Many subjects with CF have essential fatty acid deficiency, characterized by decreased levels of linoleic acid and an increased triene/tetraene ...

DESCRIPTION (provided by applicant): Hemorrhagic fever viruses are of serious worldwide health concern as well as potential biological weapons. Lassa fever virus in particular annually infects several hundred thousand individuals in West Africa, and the export of this pathogen outside of this region, either intentionally or unintentionally, presents a serious risk to the developed countries of the ...

DESCRIPTION (provided by applicant): The overall goal of this project is to develop broad-spectrum antibiotics against Yersinia pestis and other important human pathogens. The potential use of engineered, multi-drug-resistant strains as agents of bioterrorism necessitates the development of new anti-Y. pestis therapies. This is a challenging goal, since the last novel class of broad-spectrum antib ...

DESCRIPTION (provided by applicant): The ultimate goal of the research described in this application is to develop an economical, safe and effective countermeasure to defend the American public from a bioterrorist attack by botulinum toxin. We aim to be the manufacturer of an antibody or antibody mixture, derived form transgenic plants; that win effectively neutralize botulinum toxin and will supp ...

DESCRIPTION (provided by applicant): Concern over the use of variola virus as a biological weapon has prompted interest in development of small molecule therapeutics for smallpox. Variola virus is highly transmissible and causes severe disease with high mortality rates. Currently, there is no FDA-approved drug for prevention or treatment of smallpox. The overall goal of this smallpox antiviral pro ...

DESCRIPTION (provided by applicant): The LIGO-069-136 Phase II renewal project is a critical path research and development plan designed to qualify an anti-inflammatory monoclonal antibody product for approval of an investigative new drug (INO) for chronic bronchitis. The proposed mechanism of action of LlGO-069-136 is the prevention of neutrophil and monocyte adherence to endothelial cells, and s ...

DESCRIPTION (provided by applicant): Cepheid Inc and the New Jersey Medical School have developed an assay system that integrates sample processing and real-time PCR diagnosis into a single, hands free process. During the successful completion of a phase I STTR application we demonstrated that this system simultaneously detect the presence of Mycobacterium tuberculosis (TB) and diagnose rifampin r ...

DESCRIPTION (provided by applicant): Approximately 800,000 persons in the U.S. suffer an acute stroke each year. There presently is no neuroprotective agent that can be given to patients with acute stroke, and stroke is the third leading cause of death. The costs for rehabilitation of patients that survive a stroke is greater than $40 billion per year in the U.S. The reason that an effective neur ...

DESCRIPTION (provided by applicant): The goal of this research is develop therapeutic products for Cryptosporidium parvum which can be made at a scale and cost which are feasible for delivery to large populations of patients or individuals at risk, as may be necessary in countering bioterrorism, or in protecting field-deployed armed forces. Our approach is to develop recombinant neutralizing mon ...

DESCRIPTION (provided by applicant): We have shown that a plant-produced recombinant protein derived from a human anthrax toxin receptor protein and human IgG (an immunoadhesin), neutralizes anthrax lethal toxin in cell culture assays. In this project we will show the effectiveness of this immunoadhesin in vivo, both against purified toxin and in an animal model of pulmonary anthrax (infection w ...